Steven Biesmans

Steven Biesmans joined UCB Ventures in 2021 as Principal. He is board director for UCB Ventures’ portfolio companies ViaNautis and Cenos Therapeutics and serves as board observer at Seamless Therapeutics, Walden Biosciences, and Iris Medicine, with previous observer roles at EsoBiotec and SpliceBio. Before UCB Ventures, Steven spent 12 years in preclinical drug discovery, building technology platforms and leading research programs across pharma, biotech, and academia in Europe and the United States. He holds a PhD in Neuroimmunology, an MS in Clinical Molecular Life Sciences, and completed Wharton’s Venture Capital Executive Program. Outside of work, he enjoys outdoor activities with his wife and three children, martial arts, and growing fruits and vegetables.